Document is current
Any future updates will be listed below
-
Authors
Gelev, Kyla Z. https://orcid.org/0000-0003-3980-7189
Lee, Seung Hyuk T. https://orcid.org/0000-0002-0943-6076
Alvarez, Marcus
Mancina, Rosellina M. https://orcid.org/0000-0002-1126-3071
Tavaglione, Federica https://orcid.org/0000-0002-1720-4355
Jamialahmadi, Oveis https://orcid.org/0000-0001-7139-4738
Vespasiani-Gentilucci, Umberto
Kar, Asha https://orcid.org/0009-0000-1717-1744
Wang, Zitian
Kaminska, Dorota https://orcid.org/0000-0003-1829-576X
Kaikkonen, Minna U. https://orcid.org/0000-0001-6294-0979
Männistö, Ville
Heinonen, Sini https://orcid.org/0000-0002-6342-0577
Saarinen, Tuure https://orcid.org/0000-0002-7508-4849
Juuti, Anne
Pietiläinen, Kirsi H. https://orcid.org/0000-0002-8522-1288
Pihlajamäki, Jussi https://orcid.org/0000-0002-6241-6859
Romeo, Stefano https://orcid.org/0000-0001-9168-4898
Pajukanta, Päivi https://orcid.org/0000-0002-6423-8056
- License Information
-
More Information
Article History
Received: 3 March 2025
Accepted: 18 May 2026
First Online: 3 June 2026
Competing interests
: S.R. has been consulting for AstraZeneca, GSK, Celgene Corporation, Ribo-cure AB and Pfizer in the last 5 years and received a research grant from AstraZeneca. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the paper or in the decision to publish the results. All other authors declare no competing interests.
